Viewing data from:

TIZANIDINE HYDROCHLORIDE

ANDA

TIZANIDINE HYDROCHLORIDE | A076286 | DR REDDYS LABORATORIES INC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ZANAFLEX(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 12 NDCs

Highest NADAC/Unit

$0.0319

per ea

Lowest NADAC/Unit

$0.0306

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68084064501TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19
68084064565TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19
55111018010TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19
55111018015TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19
50268076015TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19
16714017201TIZANIDINE HCL 4 MG TABLET	$0.0319	EA	Generic	—	2026-08-19

Showing 6 of 12 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain8 active DMFs4 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 156992001

SUN PHARMACEUTICAL INDUSTRIES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 157272001

TAPI NL BVTIZANIDINE HYDROCHLORIDE USP

DMF 158202002

MATRIX PHARMACORP PRIVATE LTDTIZANIDINE HYDROCHLORIDE USP

DMF 223542008

PH HEALTH LTDTIZANIDINE HYDROCHLORIDE, USP

DMF 281762014

SYMED LABS LTDTIZANIDINE HYDROCHLORIDE USP

DMF 339002019

ZYDUS LIFESCIENCES LTDTIZANIDINE HYDROCHLORIDE USP

DMF 349292020

DR REDDYS LABORATORIES LTDTIZANIDINE HYDROCHLORIDE USP (TZN-PROCESS)

DMF 414312025

SANDOZ PHARMA LTDInactiveTIZANIDINE HYDROCHLORIDE

DMF 92421991

FARCHEMIA SRLInactiveTIZANIDINE HYDROCHLORIDE

DMF 155552001

HETERO DRUGS LTDInactiveTIZANIDINE HYDROCHLORIDE

DMF 157302001

APOTEX PHARMACHEM INDIA PVT LTDInactiveTIZANIDINE HYDROCHLORIDE USP

DMF 222822008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 2MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jul 3, 2002

No patent or exclusivity listings for this strength.

#002 — EQ 4MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jul 3, 2002